Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...

NEW HAVEN, Conn., & AMSTERDAM--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Complement Pharma today announced a partnership to co-develop the preclinical C6 complement inhibitor ...

Alexion Pharmaceuticals, Inc. ALXN announced a partnership with Complement Pharma to co-develop the preclinical C6 complement inhibitor, CP010, for neurodegenerative disorders. CP010 is a humanized ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for classical complement-mediated ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition "Q32 is developing ADX-097 as a ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Soliris (eculizumab; Alexion) for use in patients with neuromyelitis ...

Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year ...